Tirzepatide price depends on which product the question is about. Mounjaro and Zepbound are FDA-approved prescription medicines, and Eli Lilly publishes their list, savings and self-pay prices. Research-grade tirzepatide is something else: a lyophilized reagent sold for laboratory research use only, priced per vial and per mg. This page sets out both sets of numbers as they stood on November 17, 2026, and keeps the two categories apart.
Quick answer: As published by Lilly on November 17, 2026, Mounjaro lists at $1,112.16 for a 28-day supply. The Lilly pages we checked list self-pay and savings prices for Zepbound, not a list price for the single-dose Pen. Zepbound self-pay starts at $299 per fill. Research-grade tirzepatide, a different product category, listed at $39.99–$199.99 per vial at US research suppliers. Vitrapep lists 10 mg at $74.99.
Two different categories, two different prices
Tirzepatide is a 39-amino-acid peptide with two non-coded amino acids (Aib) and a C20 fatty diacid attached through a linker at lysine 20. It acts at both the GIP and GLP-1 receptors (Coskun et al., 2018). The name covers two kinds of product:
- Prescription medicines. Mounjaro and Zepbound are FDA-approved, made and tested under FDA drug manufacturing rules, and dispensed by a pharmacy on a prescription. They have list prices, insurance rules and manufacturer savings programs.
- Research reagents. Research-grade tirzepatide is a lyophilized powder sold for laboratory work. FDA has not reviewed it as a drug. It is for laboratory research use only, not for human or veterinary use.
One is not a substitute for the other, and the prices below are not a comparison. FDA has warned companies that sold tirzepatide and other GLP-1 products labeled “for research purposes” or “not for human consumption” directly to consumers, and it urges consumers not to purchase them (FDA, 2026). Our semaglutide price page draws the same line for semaglutide.
The approved tirzepatide products
FDA records show two brand names, each sold as single-dose pens, vials and a KwikPen:
- Mounjaro (NDA 215866) was first approved on May 13, 2022 (FDA, Drugs@FDA). Its label covers glycemic control in type 2 diabetes, for adults and children 10 and older, and cardiovascular risk reduction in high-risk adults with type 2 diabetes (Mounjaro label, DailyMed).
- Zepbound (NDA 217806) was first approved on November 8, 2023 (FDA, Drugs@FDA). Its label covers reducing excess body weight and keeping it off long term in adults with obesity, or overweight with a weight-related condition, and moderate to severe obstructive sleep apnea in adults with obesity (Zepbound label, DailyMed).
Mounjaro and Zepbound prices as Lilly publishes them
A list price is the price a manufacturer sets before discounts or rebates. Insurance and savings programs change what a person pays. These are the figures on Lilly’s Mounjaro and Zepbound sites, as of November 17, 2026:
Lilly list, savings and self-pay prices for tirzepatide medicines, as published November 17, 2026
| Product | List price | Lilly savings or self-pay price |
|---|---|---|
| Mounjaro | $1,112.16 for a 28-day supply | As little as $25 per fill with commercial coverage; as low as $499 per 1-month fill without it |
| Zepbound single-dose Pen | Not shown on the Lilly pages checked | As little as $25 per fill with commercial coverage; as low as $499 per 1-month fill without it |
| Zepbound KwikPen | Not shown on the Lilly pages checked | Self-pay $299 to $699 per 1-month fill, by strength; $299, $399 or $449 with Lilly’s KwikPen card |
| Zepbound vials | Not shown on the Lilly pages checked | Self-pay from $299 per 1-month fill |
Sources: Lilly’s Mounjaro FAQ, Mounjaro savings page and Zepbound savings page, all read November 17, 2026. Lilly states that these cards expire and savings end on December 31, 2026. The $499 offers apply to commercially insured patients whose plan does not cover the medicine. Mounjaro self-pay is offered through LillyDirect, with no price on the page checked. A prescription is required.
Two more points from Lilly’s own pages:
- Card caps. Annual card savings are capped at $1,950 for Mounjaro with coverage, $8,411 for Mounjaro without coverage and $1,300 for the Zepbound Pen with coverage (Lilly, 2026b; Lilly, 2026c).
- Medicare. Lilly says eligible Medicare Part D patients prescribed Zepbound for weight management can get it through the Medicare GLP-1 Bridge for no more than $50 a month (Lilly, 2026c).
Research-grade tirzepatide prices
Research-grade tirzepatide is priced like any research peptide: per vial and per mg. We checked US supplier product pages on November 17, 2026, and recorded the listed single-vial price. Prices exclude shipping, codes and pack discounts.
Research-grade tirzepatide prices at US suppliers, checked November 17, 2026
| Supplier | Vial size | Listed price | Price per mg |
|---|---|---|---|
| Zeptix Labs (listed as GLP-2 T) | 10 mg | $79.99 | $8.00 |
| Zeptix Labs (listed as GLP-2 T) | 30 mg | $110.00 | $3.67 |
| Purely Peptides | 10 mg | $74.99 | $7.50 |
| Purely Peptides | 30 mg | $89.99 | $3.00 |
| Purely Peptides | 60 mg | $129.99 | $2.17 |
| PS Peptides | 10 mg | $54.99 | $5.50 |
| PS Peptides | 30 mg | $114.99 | $3.83 |
| PS Peptides | 60 mg | $199.99 | $3.33 |
| American Peptides (listed as AP-TRZ-2, code LY3298176) | 10 mg | $100.00 | $10.00 |
| Peptide Giants (listed as TRZ-2) | 10 mg | $39.99 | $4.00 |
| Vitrapep | 10 mg | $74.99 | $7.50 |
Sources: supplier product pages listed in the references, read November 17, 2026. Price per mg is the listed price divided by the vial size. Zeptix Labs had a buy-one-get-one offer on 10 mg. PS Peptides size prices are from the store’s own data for the listing. American Peptides gives a research code and CAS number, not the name tirzepatide. Peptide Giants names no compound and priced only 10 mg. All are sold for laboratory research use only.
Across the listings we checked, research-grade tirzepatide ran from $39.99 to $199.99 per vial and from $2.17 to $10.00 per mg. Larger vials cost less per mg because filling, labeling and lot testing cost about the same at any size.
What moves research tirzepatide prices
The levers are the same ones covered in our peptide prices explainer:
- Synthesis length. Peptides are built one amino acid at a time, and each coupling step loses some yield. A 39-residue chain costs more per mg than a short one (Verlander, 2007).
- Chemistry. The two Aib residues and the fatty diacid side chain each add synthesis and purification work (Coskun et al., 2018).
- Purity and testing. HPLC purity and mass spectrometry identity from an outside laboratory, ideally one accredited to ISO/IEC 17025, cost money per lot.
- Promotions. Buy-one-get-one offers and sale prices change the effective price from week to week.
Red flags in very cheap listings
A low price is not proof of a problem, but it leaves less room for the steps that confirm what is in the vial. Look closer at these signs:
- No compound name. A code such as TRZ-2 is fine if the page or certificate also names the compound or gives its CAS number. The TRZ-2 page we checked did neither, so identity could not be checked against the label.
- A price far below the range. The lowest vial price in Table 2 was $39.99 for 10 mg. Below that, ask for the lot’s test report first.
- Brand-name comparisons. A research listing that names Mounjaro or Zepbound, or prices itself against them, is pitching a reagent as a medicine.
- Human-use language. FDA has acted against GLP-1 products sold under research labels with dosing instructions for consumers (FDA, 2026). A research listing should carry none.
- No lot-specific certificate. A credible certificate names the lot, the laboratory, the test date, HPLC purity and a mass spectrometry identity result. Our guide to reading a certificate of analysis walks through each field.
What Vitrapep charges for tirzepatide
Vitrapep lists tirzepatide as a 10 mg lyophilized vial at $74.99, or $7.50 per mg. Store prices may still change before launch. It is a research reagent, sold for laboratory research use only and not for human or veterinary use. It is not Mounjaro or Zepbound, and it is not a substitute for any prescription medicine. For sourcing, see where to buy tirzepatide. For background, see our tirzepatide guide and tirzepatide vs semaglutide.

Tirzepatide
Specifications and the current lot’s test documentation for the tirzepatide sold for laboratory research.
Frequently asked questions about tirzepatide price
What is the list price of Mounjaro and Zepbound?
As of November 17, 2026, Lilly gave the current list price of Mounjaro as $1,112.16 for a 28-day supply (Lilly, 2026a). The Lilly pages we checked list self-pay and savings prices for Zepbound, not a list price for the single-dose Pen.
What does tirzepatide cost without insurance?
Lilly’s Zepbound self-pay prices start at $299 per fill of the KwikPen or vials, and a prescription is required. KwikPen fills run $299 to $699 by strength, or $299 to $449 with Lilly’s KwikPen card (Lilly, 2026c).
Is research-grade tirzepatide the same as Mounjaro or Zepbound?
No. Mounjaro and Zepbound are FDA-approved prescription medicines. Research-grade tirzepatide is a laboratory reagent that FDA has not reviewed as a drug. It is for laboratory research use only, not for human or veterinary use, and not a substitute for any prescription medicine.
How much does research-grade tirzepatide cost per mg?
At the US research suppliers we checked on November 17, 2026, listed prices ran from $2.17 to $10.00 per mg, depending on supplier and vial size. Vitrapep lists 10 mg at $74.99, or $7.50 per mg.
What to know now
- Mounjaro lists at $1,112.16 for a 28-day supply. The Lilly pages checked give no Zepbound Pen list price.
- Savings and self-pay prices are lower. From $25 with commercial coverage; Zepbound self-pay from $299. All require a prescription.
- Lilly’s cards end December 31, 2026. Zepbound reimbursement claims are due by March 31, 2027.
- Research-grade tirzepatide is a different category. It is a laboratory reagent at $2.17 to $10.00 per mg, not for human or veterinary use.
- Vitrapep lists 10 mg at $74.99. That is $7.50 per mg, within the research supplier range.
What we’re watching
First, December 31, 2026, when Lilly’s Mounjaro and Zepbound savings cards are set to expire. Second, the savings and self-pay terms Lilly sets for 2027. Third, FDA enforcement against GLP-1 products sold to consumers under research labels, which FDA last updated on October 1, 2026.